Table 1.
Characteristics and outcomes of each cohort.
| Parameters | Prostate Cancer (n = 1122) | Control Group (n = 444) | p |
|---|---|---|---|
| Age, yrs; median (IQR) | 66 (61–70) | 64 (59–70) | 0.24 |
| Body Mass Index, kg/m2; mean (SD) | 26.5 (3.6) | 25.7 (4.3) | 0.01 |
| First PSA measurement; median (IQR) | 9.9 (6.7–16.3) | 6.4 (4.8–10.3) | 0.93 |
| Statin use, n (%) | 252 (22.5) | 83 (18.7) | 0.10 |
| Type of statins, n (%) | |||
| Simvastatin | 160 (63.5) | 45 (54.2) | 0.13 |
| Atorvastatin | 44 (17.5) | 22 (26.5) | 0.07 |
| Rosuvastatin | 22 (8.7) | 7 (8.4) | 0.93 |
| Pravastatin | 26 (10.3) | 9 (10.8) | 0.89 |
| Gleason score, n (%) | |||
| 6 | 219 (19.5) | ||
| 7 | 661 (58.9) | ||
| ≥8 | 242 (21.6) | ||
| Pathological T-stage, n (%) | |||
| T2b or lower | 104 (9.3) | ||
| T2c or higher | 533 (47.5) | ||
| Missing | 485 (43.2) | ||
| ESMO-classification, n (%) | |||
| Low Risk | 103 (9.2) | ||
| Intermediate Risk | 588 (52.4) | ||
| High Risk | 431 (38.4) | ||
| Surgery, n (%) | |||
| Received prostate surgery | 728 (64.9) | ||
| No prostate surgery | 394 (35.1) | ||
| PSA-progression after surgery, n (%) | |||
| No PSA-progression | 365 (87.7) | ||
| PSA-progression | 51 (12.3) | ||
| Follow-up in months; mean (SD) | 50.0 (33.3) |
BMI: body mass index; PSA: prostate-specific antigen.